Alendronic acid-d6 is a deuterium labeled Alendronic acid. This bisphosphonate acts as a farnesyl diphosphate synthase (FDPS) inhibitor, effectively inhibiting osteoclast-mediated bone resorption. It has shown efficacy in treating postmenopausal osteoporosis, malignant hypercalcemia, and Paget's disease. Stable heavy isotopes, such as deuterium, are incorporated into drug molecules primarily as tracers for quantitative analysis during drug development, noting their potential to influence pharmacokinetic and metabolic profiles.
- Used as a tracer.
- Functions as an internal standard for quantitative analysis (NMR, GC-MS, LC-MS).
- Inhibits osteoclast-mediated bone resorption.
- Effective in treating postmenopausal osteoporosis, malignant hypercalcemia, and Paget's disease.
- Deuteration can affect pharmacokinetic and metabolic profiles of drugs.